NSW: 1,180 peptide-linked ER visits, most name retatrutide

Emergency departments in New South Wales, Australia’s most populous state, recorded 1,180 presentations associated with peptide use between July 1, 2025 and September 30, 2026, according to NSW Health surveillance data released with a warning from the state’s Minister for Health on October 19 (Sydney time). Monthly presentations rose from five in July 2025 to more than 217 in September 2026. The release says such visits were previously very rare.

It is the first time we have seen a health department publish an emergency-room count for the unapproved peptide trade at this scale. It is also a count with clear limits, set out below.

What the data shows

The ministerial release gives the headline numbers and the trend. More detail from the same NSW Health report appeared in Australian coverage the same day:

• Retatrutide dominates. The Newcastle Herald reported that retatrutide was mentioned in 833 presentations, and that the generic word “peptide” or the names of other unapproved peptides came up in 445. That puts retatrutide in roughly seven of every ten visits in the data. Eli Lilly’s triple-agonist is still in clinical trials and, as the Herald put it, is “not approved anywhere in the world”.
• Most visits were not admissions, but a sizeable minority were. About 18 percent of presentations resulted in a hospital admission. The most common primary diagnoses were gastrointestinal (abdominal pain, nausea, vomiting), cardiovascular (including chest pain), and allergic reactions or medication-related adverse events.
• Young adults are most of it. People aged 25 to 34 made up 32 percent of presentations, 35 to 44 made up 26 percent and 16 to 24 made up 25 percent. Men and women were close to even (51 and 49 percent).
• It is concentrated in Sydney’s south and west. South Western Sydney recorded 252 presentations, the most of the state’s 15 districts, followed by South Eastern Sydney (173) and Western Sydney (158).

NSW Health also says it is getting reports of serious illness from clinicians, “including kidney damage and liver injury,” through the NSW Poisons Information Centre, and that it works with the Therapeutic Goods Administration and, where relevant, police to trace the source of a product when a seriously ill patient is identified.

What the count does not show

Three caveats matter for anyone citing this number.

First, it is a floor. The Sydney Morning Herald reported that the report “only captures patients whose peptide use was disclosed.” Visits where a patient did not mention a peptide, or where triage notes did not record it, are not in the 1,180.

Second, it measures association, not cause. A presentation “associated with peptide use” means the use was recorded; it does not establish that the product caused the illness. The same caution applies to every adverse-event tally, including the US reports discussed below.

Third, nobody knows what was in the vials. NSW Health’s warning is explicit that these products “may contain unknown or harmful substances, be incorrectly labelled or contain different strengths or ingredients than advertised.” A visit coded as retatrutide is a visit where someone said they used a product sold as retatrutide. The SMH reported a September TGA case in which testing of a product sold as retatrutide found semaglutide instead. NSW Chief Health Officer Dr. Kerry Chant put it this way in the release: “A professional looking website, a label, purity claim, reviews, or influencer endorsement is not proof of what is inside the product.”

Why this matters outside Australia

The products named in the NSW warning (BPC-157, GHK-Cu, TB-500, retatrutide, CJC-1295) are the same ones sold online to US buyers, usually labeled for “research use only.” In the United States, the visible safety signals so far have come from individual reports rather than population counts. CBS News reported on October 13 that FDA’s adverse event reporting system received reports of two deaths after people used products claiming to be retatrutide, one involving a 41-year-old woman and one a 49-year-old patient. CBS said the details are unverified and that the reports do not show the drug caused either death.

We did not find a published US emergency-department count comparable to the NSW figure. What exists on the US side is enforcement: FDA warning letters to sellers of research-labeled retatrutide, covered in our September 2025 report, and Eli Lilly’s civil suits against sellers, two more of which Lilly has just dropped with prejudice. The NSW data is the clearest public picture yet of what the same market looks like from inside a hospital system.

What to watch

Minister Ryan Park told ABC News he expects the issue to be “a topic for conversation with health ministers over the next few months.” NSW Health says it will keep monitoring emergency presentations, poison-center calls and clinician reports. The questions we will follow: whether other Australian states publish comparable data, whether the TGA releases more product-testing results, and whether any US health department or poison-control system publishes a similar count.

Amino Wire does not give medical advice. NSW Health’s own guidance is on its peptide products page.